Overview
- 19 inspections across 19 sites are on record.
- 44 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-05-20.
At a glance
Inspections
19
Sites
19
Observations
44
Career since
Apr 2024
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Merck Sharp & Dohme LLC | 20 May 2026 | Biologics | On file |
| PPD Development, L.P. | 1 May 2026 | Biologics | |
| Dendreon Pharmaceuticals LLC | 25 Mar 2026 | Biologics | On file |
| Novartis Pharmaceuticals Corporation | 6 Feb 2026 | Biologics | On file |
| Simtra US LLC | 11 Dec 2025 | Biologics | View 483 → |
Sites inspected
Merck Sharp & Dohme LLCDurham, United States1 insp.
PPD Development, L.P.Middleton, United States1 insp.
Dendreon Pharmaceuticals LLCSeal Beach, United States1 insp.
Novartis Pharmaceuticals CorporationMorris Plains, United States1 insp.
Simtra US LLCBloomington, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Christian Lynch2 shared
Richard L Bartlett2 shared
Peng Zhou2 shared
Priscilla M Pastrana2 shared
Ivan E Reyes2 shared
Annette Melendez2 shared
Emily B Camire1 shared
Burnell M Henry1 shared
Esther A Ofori1 shared
Gene D Arcy1 shared
Full investigator report
Get the verbatim findings behind Lizaida Perez's 44 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site